TRELEGY ELLIPTA (FLUTICASONE FUROATE/UMECLIDINIUM BROMIDE/VILANTEROL TRIFENAT)

Moderate

• amoxicil-clarithromy-lansopraz

• Avelox

• Avelox Abc Pack

• Avelox In Nacl (iso-osmotic)

• Biaxin

• Biaxin Xl

• Biaxin Xl Pak

• Cipro

• Cipro In D5W

• Cipro Xr

• ciprofloxacin

• ciprofloxacin (mixture)

• ciprofloxacin in D5W

• clarithromycin

• Erythrocin

• erythromycin

• erythromycin-sulfisoxazole

• itraconazole

• K-tab

• ketoconazole

• Klor-con

• Klor-con 10

• Klor-con M10

• Klor-con M15

• Klor-con M20

• Levaquin

• Levaquin In 5 % Dextrose

• levofloxacin

• levofloxacin in D5W

• Medi-lyte

• moxifloxacin

• moxifloxacin in NaCl (iso-osm)

• norfloxacin

• Noroxin

• ofloxacin

• Omeclamox-pak

• omeprazole-clarith-amoxicillin

• Onmel

• potassium chloride

• potassium citrate

• potassium Cl-calcium phos-mag

• Prevpac

• sodium Cl-potassium chloride

• Sporanox

• Sporanox Pulsepak

• Thermotabs

• Urocit-k 10

• Urocit-k 15

• Urocit-k 5

Moderate

• Angle-closure glaucoma

• Benign prostatic hyperplasia

• Bladder outflow obstruction

• Cardiac arrhythmia

• Cataracts

• Diabetes mellitus

• Hypertension

• Hypothalamic-pituitary insufficiency

• Open angle glaucoma

• Oral candidiasis

• Osteopenia

• Osteoporosis

• Seizure disorder

• Thyrotoxicosis

• Urinary retention

Fluticasone (inhal)

• Severity Level:

  2

• Additional Notes: Current evidence supports use of inhaled corticosteroids for asthma tx in preg

Umeclidinium

• Severity Level:

  2

• Additional Notes: Insufficient human data available

Vilanterol

• Severity Level:

  C

• Additional Notes: Insufficient human data available

Contraindicated

None

Precaution Exists

Fluticasone (inhal, Nasal)

Systemic products excreted in rats; caution advised with nasal administration

Insufficient human data; excreted in rats

Insufficient data for vilanterol; other beta-agonists are excreted in milk

Umeclidinium

Systemic products excreted in rats; caution advised with nasal administration

Insufficient human data; excreted in rats

Insufficient data for vilanterol; other beta-agonists are excreted in milk

Vilanterol (inhal)

Systemic products excreted in rats; caution advised with nasal administration

Insufficient human data; excreted in rats

Insufficient data for vilanterol; other beta-agonists are excreted in milk

No Known Risk

None

Contraindicated

None

Precaution Exists

Fluticasone (inh)

Musculoskeletal-Use with caution in patients with osteoporosis. Decreases in bone mineral density (BMD) has been observed with long-term administration of products containing inhaled corticosteroids.

Urogenital-Use caution in men with benign prostatic hyperplasia; may decrease urinary flow and cause urinary retention. Other-Use caution in elderly with narrow angle glaucoma. Gastrointestinal-Anticholinergic effects may worsen constipation in predisposed elderly.

Cardiovascular-Use caution in severe cardiovascular diseases, particularly coronary insufficiency, since beta-agonists increase heart rate and blood pressure. Endocrine-Use caution in poorly controlled diabetes or hyperthyroidism.

BEERS: N     HEDIS: N     STOPP: N

Umeclidinium

Musculoskeletal-Use with caution in patients with osteoporosis. Decreases in bone mineral density (BMD) has been observed with long-term administration of products containing inhaled corticosteroids.

Urogenital-Use caution in men with benign prostatic hyperplasia; may decrease urinary flow and cause urinary retention. Other-Use caution in elderly with narrow angle glaucoma. Gastrointestinal-Anticholinergic effects may worsen constipation in predisposed elderly.

Cardiovascular-Use caution in severe cardiovascular diseases, particularly coronary insufficiency, since beta-agonists increase heart rate and blood pressure. Endocrine-Use caution in poorly controlled diabetes or hyperthyroidism.

BEERS: N     HEDIS: N     STOPP: Y

Vilanterol

Musculoskeletal-Use with caution in patients with osteoporosis. Decreases in bone mineral density (BMD) has been observed with long-term administration of products containing inhaled corticosteroids.

Urogenital-Use caution in men with benign prostatic hyperplasia; may decrease urinary flow and cause urinary retention. Other-Use caution in elderly with narrow angle glaucoma. Gastrointestinal-Anticholinergic effects may worsen constipation in predisposed elderly.

Cardiovascular-Use caution in severe cardiovascular diseases, particularly coronary insufficiency, since beta-agonists increase heart rate and blood pressure. Endocrine-Use caution in poorly controlled diabetes or hyperthyroidism.

BEERS: N     HEDIS: N     STOPP: N

No Known Risk

None